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ABSTRACT
There is a significant controversy on whether race should be a factor in 
considering active surveillance for low-risk prostate cancer. To address this question, 
we analyzed a multi-institution database to assess racial disparity between African-
American and White-American men with low risk prostate cancer who were eligible 
for active surveillance but underwent radical prostatectomy. A retrospective analysis 
of prospectively collected clinical, pathologic and oncologic outcomes of men with 
low-risk prostate cancer from seven tertiary care institutions that underwent radical 
prostatectomy from 2003–2014 were used to assess potential racial disparity. Of 
the 333 (14.8%) African-American and 1923 (85.2%) White-American men meeting 
active surveillance criteria, African-American men were found to be slightly younger 
(57.5 vs 58.5 years old; p = 0.01) and have higher BMI (29.3 v 27.9; p < 0.01), pre-
op PSA (5.2 v 4.7; p < 0.01), and maximum percentage cancer on biopsy (15.1% 
v 13.6%; p < 0.01) compared to White-American men. Univariate and multivariate 
analysis demonstrated similar rates of upgrading, upstaging, positive surgical 
margin, and biochemical recurrence between races. These results suggest that 
single institution studies recommending more stringent AS enrollment criteria for 
AA men with a low-risk prostate cancer may not capture the complete oncologic 
landscape due to institutional variability in cancer outcomes. Since all seven 
institutions demonstrated no significant racial disparity, current active surveillance 
eligibility should not be modified based upon race until a prospective study has 
been completed.
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INTRODUCTION
Prostate cancer (PCa) affects more men than any 
other non-cutaneous malignancy. In 2017, 26,730 men are 
estimated to die from the disease [1]. Widespread prostate 
specific antigen (PSA) screening over the past two 
decades has coincided with an increase in the incidence of 
low-risk PCa that is unlikely to cause significant morbidity 
or mortality. Two separate PCa-screening studies have 
raised concerns on the harms associated with over-treating 
men with low-risk disease [2–4]. As a result, increasing 
emphasis has been placed on the role of active surveillance 
(AS) for men with low-risk PCa. 
AS allows the opportunity to postpone or completely 
avoid definitive treatment in men with low-risk disease 
by periodically monitoring for evidence of disease 
progression [5]. Currently, there is no uniform consensus 
on the eligibility criteria for AS. The decision to enter 
an AS protocol is individually tailored to each patient’s 
perceived cancer risk and personal preference, while 
also minimizing the chance of an undetected clinically 
significant tumor [6]. Regardless, the risk of understaging 
low-risk PCa is as high as 38% [7, 8]. It is therefore of 
critical importance to accurately identify those men who 
may benefit from immediate treatment versus those 
who may safely undergo conservative management and 
surveillance.
It is well established that there is a significant racial 
disparity in PCa. Multiple investigators have reported 
that African-American (AA) men are at increased risk for 
aggressive cancer [6, 9–13] and have a higher incidence of 
disease, worse pathologic outcomes, and higher mortality 
rates than White-American (WA) men [6, 14–17]. The 
underlying etiology of this racial disparity is likely 
heterogeneous and is thought to be due to a complex 
interaction of disease biology, access to healthcare, patient 
preferences, and socioeconomic factors. Due to such 
complexities, it remains unclear whether AS is an equally 
effective and valid management option for AA men. 
Currently, there is a significant debate on whether 
the same AS eligibility criteria should be applied to all 
racial groups with low-risk PCa, or varied according to 
race [18]. Some studies have shown comparable rates 
of upgrading and upstaging, regardless of race, in men 
eligible for AS who underwent radical prostatectomy (RP) 
[19, 20]. On the contrary, an AS cohort found AA men 
to have a higher rate of disease progression compared to 
WA men [21]. In a separate study, we have found that AA 
men eligible for AS had worse clinicopathologic features 
on final surgical pathology compared to WA patients [22] 
and a recent large single institution study indicated that 
AA men had worse pathologic features following RP than 
a comparison group of WA men [23]. Accordingly, some 
investigators have suggested more stringent AS inclusion 
criteria specifically for AA men [24]. This study’s aim 
was to clarify the feasibility of making the AS enrollment 
criteria for AA men with localized PCa more stringent, 
by retrospectively analyzing prospectively collected PCa 
databases from seven tertiary care institutions. 
RESULTS
A total of 2256 patients from seven institutions 
met the inclusion criteria (Table 1). Baseline clinical 
characteristics between the AA (n = 333) and WA (n = 
1923) men are shown in Table 2. AA men had significantly 
higher BMI (29.3 v 27.9; p < 0.01) and were younger 
compared to the WA patients (57. v 58.5; p = 0.01). AA 
men also had higher pre-op PSA (5.2 v 4.7; p < 0.01). 
In addition, AA men were more likely to have multiple 
positive biopsy cores (53.1 v 47.6%; p < 0.01) and a 
higher rate of maximum percentage cancer on biopsy 
(15.1 v 13.6%; p < 0.01). However, WA men had a higher 
rate of T2a disease (11.7% v 4.2%, p < 0.01).
When pathologic characteristics were examined 
from the pooled data, there was no racial disparity in the 
rate of upstaging, upgrading, and positive surgical margin 
(p = 0.808, p = 0.1169, p = 0.1929 respectively) (Table 3). 
We next carried out a multi-variable analysis using 
variables that are readily available; race, age, BMI, PSA 
at diagnosis, single versus multiple positive biopsy cores 
and the maximum % cancer per core (Table 4). The results 
demonstrated that race was not associated with upgrading, 
upstaging, positive surgical margin rate, BCR when all 
institutions were combined. 
Because data for this study were collected from 
seven institutions, we next stratified the results by 
individual centers (Table 5). The results demonstrated 
large inter-institutional differences in rates of upstaging 
and upgrading in AA men, ranging from 0–10.8% and 
27–47.3%, respectively. In addition, the positive surgical 
margin and BCR rates in AA men varied from 7.7% to 
22.9% and 0% to 13.5%. Despite such wide range among 
the participating centers, no difference between AA and 
WA men was observed within each institution for the 
pathologic outcomes and BCR rate.
DISCUSSION
Our study of pooled data from seven tertiary 
institutions in the United States has one of the largest 
sample size to date on AA men eligible for AS (n = 333). 
AA men who were eligible for AS but chose surgery did not 
have significantly worse pathologic and oncologic outcome 
when compared to WA men. In addition, multi-variate 
analysis accounting for baseline clinical characteristics and 
institution did not demonstrate that race was an independent 
predictor of adverse outcomes. Collectively, these findings 
suggest that universally recommending modifications in AS 
criteria for AA men is premature at the present time. 
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Table 2: Patient characteristics
Clinical Characteristics
White Men AA Men
p-value(n = 1923) (n = 333)
Age, years 0.01t
 Mean 58.5 57.5
 95% CI (58.2–58.8) (56.7–58.2)
Body Mass Index <0.01t
 Mean 27.9 29.3
 95% CI (27.7–28.1) (28.7–30.0)
 PSA <0.01t
 Mean 4.7 5.2
 95% CI (4.6–4.8) (5.0–5.4)
 Biopsy Gleason 6 6
Clinical Stage (%) <0.01t
 T1a 11 (0.6) 1 (0.3)
 T1c 1686 (87.7) 318 (95.5)
 T2a 226 (11.7) 14 (4.2)
Positive Cores (%) 0.1468*
 1 1007 (52.4) 156 (46.9)
 2 558 (29.0) 112 (33.6)
 3 358 (18.6) 65 (19.5)
Max. % Cancer per Core <0.05t
 Mean 13.6 15.1
 95% CI (13.2–14.1) (13.7–16.5) 
 PSA Density 0.0176t
 Mean 0.100 0.109 
 95% CI  (.096–.104) (.103–.114) 
tT-test.
ttFisher’s Exact.
*chisq test.
Table 1: Number of patients contributed by each participating institution
Institution
Number of Patients
WA AA
1 267 75
2 40 37
3 68 47
4 85 47
5 669 74
6 663 13
7 131 40
Total 1923 333
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Table 3: Pathologic outcome
Pathologic Characteristics
White Men AA Men
p-value
(n = 1923) (n = 333)
Upstage 7.3% 6.9% 0.808*
Pathologic Gleason
≤6 1269 (66.0) 203 (61.0) 0.1982*
7 627 (32.6) 124 (37.2)
≥8 27 (1.4) 6 (1.8)
Upgrade (%) 34.0% 38.4% 0.1169*
Path Weight (g) 52.7 (51.8–53.6) 53.7 (51.31–56.2) 0.4276t
Positive Surgical Margin 12.1% 14.7% 0.1929*
tT-test.
*chisq test.
Table 4: Multi-variate analysis
Upgrade Odds Ratio Std. Error P 95% CI: Lower 95% CI Upper
Race: AA vs WA 1.18 0.14 0.22 0.90 1.56 
Age, years 1.03 0.01 <0.01 1.01 1.04
BMI 1.02 0.01 <0.03 1.0 1.05
PSA at diagnosis, ng/ml 1.14 0.03 <0.01 1.09 1.20
Biopsy Cores: Single vs Multiple Positive 1.50 0.10 <0.01 1.22 1.83
Max % Cancer Core 1.01 0.005 <0.01 1.00 1.02
Upstage Odds Ratio Std. Error P 95% CI: Lower 95% CI Upper
Race: AA vs WA 0.82 0.27 0.44 0.48 1.38
Age, years 1.03 0.01 0.02 1.00 1.06 
BMI 1.04 0.02 0.05 1.00 1.08
PSA at diagnosis, ng/ml 1.16 0.04 <0.01 1.06 1.26
Biopsy Cores: Single vs Multiple Positive 1.40 0.19 0.08 0.96 2.03
Max % Cancer Core 1.01 0.01 0.12 1.00 1.03
Positive Surg. Margin Odds Ratio Std. Error P 95% CI: Lower 95% CI Upper
Race: AA vs WA 1.17 0.19 0.42 0.80 1.71
Age, years 1.00 0.01 0.92 0.98 1.02
BMI 1.04 0.02 <0.01 1.01 1.07
PSA at diagnosis, ng/ml 1.10 0.04 <0.01 1.02 1.19
Biopsy Cores: Single vs Multiple Positive 1.10 0.15 0.53 0.81 1.49
Max % Cancer Core 1.02 0.01 <0.01 1.00 1.03 
Biochemical Recurrence Hazard Ratio Std. Error P 95% CI: Lower 95% CI Upper
Race: AA vs WA 1.56 0.40 0.27 0.71 3.46
Age, years 1.04 0.02 0.09 0.99 1.09
BMI 0.96 0.04 0.28 0.89 1.03
PSA at diagnosis, ng/ml 1.14 0.08 0.10 0.98 1.32 
Biopsy Cores: Single vs Multiple Positive 1.4 0.33 0.31 0.73 2.70
Max % Cancer Core  0.99 0.02 0.72 0.96 1.03
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The inter-institutional differences detected in the 
present study underscore the controversy surrounding AS 
and AA men. Previously, in a two-institution study, we 
have suggested that in men with low-risk PCa, AA men 
are more likely to have aggressive pathologic features 
than WA men [25]. Simultaneously, similar findings 
were reported using a more in-depth review of a single-
institution database [23]. More recently, prospective AS 
cohorts with a relatively small sample size of AA men 
have supported the concept that low-risk PCa is inherently 
more aggressive in AA men [19]. Conversely, Jalloh 
et al. did not find a difference in the rates of upgrading 
and upstaging between AA and WA men following RP 
[19]. In this framework of contradicting results, our study 
provides the first clear evidence for significant inter-
institutional differences in outcome for AA men with a 
low-risk prostate cancer. 
In the present study, the rates of upstaging and 
upgrading in AA men among the seven participating 
institutions varied widely [0–10.8% (upstaging) and 
27–47.3% (upgrading)]. In addition, the positive surgical 
margin and BCR rates in AA men varied from 7.7% to 
22.9% and 0 to 13.5%, respectively. The reasons for 
these institutional variations in PCa outcomes are likely 
to be complex. Community and regional factors such 
as access to care, cancer screening, and lifestyle may 
significantly affect patient decisions and outcomes [26]. 
One compelling possibility is the subjective nature 
of pathologic interpretations. Indeed, inter-observer 
variability on RP specimens among pathologists has 
been reported to be as high as 30% [27]. An alternative 
explanation involves the heterogeneity among surgeons 
and subtle nuances of surgical techniques unique to each 
institution. 
Results of the present study also shed light on 
the optimal design of potential clinical trials that will 
address racial disparity and AS. Herein, the pathologic 
and oncologic outcome in men with low-risk PCa varied 
widely. Therefore, any pooled data may reflect the bias 
of one institution if the accrual is disproportionate. Thus, 
optimal study design in the future should include a well-
balanced accrual of patients from multiple sites. In short, 
any future prospective studies on AS in AA men should 
consist of multiple institutions with proportionate accrual.
Despite the large sample size reported to date on AS 
and racial disparity, this study has limitations. First, it is a 
retrospective study of patients who all underwent surgery. 
Thus, the study population in this investigation is not an 
AS cohort. Nevertheless, the findings should inform design 
of a prospective trial on AS in AA men. Second, due to 
the complexity of gathering data from multiple institutions, 
many potential confounding variables were unable to be 
accounted for; such as family history of cancer, PSA-
velocity and socioeconomic status. These variables may 
have helped better account for institutional differences. 
Third, all institutions are tertiary care academic medical 
centers in major urban areas. Accordingly, the current 
findings may not be applicable to rural or community 
based practices due to selection bias. Fourth, the cohort 
is entirely from the pre MRI/US fusion biopsy era. Thus, 
a confirmatory study using the newer technology is 
currently being planned. Lastly, the lack of difference in 
BCR between the two races may be due to a significantly 
shorter follow-up period in AA men. We plan to analyze in 
detail the survival outcomes in our next study.
MATERIALS AND METHODS
Patients
The following seven institutions participated in 
the present study: Rutgers Cancer Institute of New Jersey 
(New Brunswick, NJ), City of Hope (Duarte, CA), Thomas 
Jefferson University (Philadelphia, PA), Temple University 
(Philadelphia, PA), Georgetown University (Washington, 
DC), Northwestern University (Chicago, IL), and University 
of Chicago (Chicago, IL). After obtaining the approval 
of the Institutional Review Board (IRB) from each site, 
prospectively collected data of men eligible for AS who 
underwent RP were analyzed retrospectively. All men who 
met Rutgers Cancer Institute’s AS criteria for low-risk PCa 
were enrolled: (1) PSA ≤10 ng/ml, (2) 3 or fewer biopsy 
Table 5: Institutional characteristics
Institution
Upstage (%) Upgrade% Positive Surgical Margin Biochemical Recurrence
Caucasian African-
American
P-value Caucasian African-
American
P-value Caucasian African-
American
P-value Caucasian African-
American
P-value
1 6.70% 8.00% 0.7 29.20% 32.00% 0.64 11.20% 10.70% 0.89 3.47% 1.33% 0.3379
2 0.00% 10.80% 0.03 32.50% 27.00% 0.6 10.00% 21.60% 0.16 2.5% 0% 1
3 4.40% 8.50% 0.36 44.70% 39.70% 0.59 19.10% 14.90% 0.55 1.47% 0% 1
4 5.90% 10.60% 0.32 32.90% 36.20% 0.7 15.70% 19.20% 0.61 6.26% 13.51% 0.2818
5 7.00% 4.10% 0.33 40.50% 47.30% 0.26 12.40% 9.60% 0.48 2.19% 2.74% 0.6745
6 9.20% 7.70% 0.85 29.90% 46.20% 0.2 9.50% 7.70% 0.82 1.1% 0% 1
7 4.58% 0.00% 0.34 29.80% 37.50% 0.35 18.90% 22.90% 0.6 4.55% 10.34% 0.3624
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cores positive out of a minimum of 12-core biopsy, (3) 
biopsy Gleason score ≤6, (4) maximum biopsy core ≤50% 
cancer, and (5) clinical stage ≤T2a. All biopsy cores were 
taken using transrectal ultrasound guidance. Following RP, 
upgrading was defined as pathologic Gleason score ≥7 and 
upstaging as pathologic stage ≥ pT3. Biochemical recurrence 
(BCR) was defined as rise in PSA on two consecutive 
measurements with the last value ≥0.2 ng/ml. The number of 
patients contributed by each institution is shown in Table 1.
Statistics
Clinical and pathologic characteristics were 
compared by race and between each institution. A multi-
variable logistic regression model was used to evaluate the 
effect of race on pathologic variables while adjusting for 
readily available clinical data (year of surgery, race, age, 
BMI, clinical stage, PSA at diagnosis, single vs multiple 
positive biopsy cores and max % cancer per core) using 
Odds ratio. Differences in continuous variables were 
assessed using the t test. Categorical values were analyzed 
using the chi-square test and Fisher’s exact test was used 
when frequencies were five or less. All statistical analyses 
were carried out using Stata SE 13 [28]. Only p-values < 
0.05 were considered statistically significant. 
CONCLUSIONS
Further investigation, including prospective AS 
trials should be undertaken before any definitive judgment 
on AS and racial disparity can be made in men with PCa. 
In the meantime, race should not be a factor in counseling 
patients with low-risk PCa given that racial disparity in 
men eligible for AS was not observed in any of the seven 
participating sites in this study.
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